摘要
目的探讨多西他赛在控制晚期非小细胞肺癌（NSCLC）胸腹水的作用。方法选取2011年1月~2014年1月我科收治的40例Ⅳ期晚期NSCLC患者,将其分为实验做和对照组,各20例。实验组患者使用多西他赛单药每3周方案静脉注射治疗至少2周期以上,再放胸腹水或不放胸腹水,对照组患者行支持治疗且放胸腹水。观察两组疗效和毒副反应。结果实验组与对照组患者在完全缓解率（25%vs 0%）、部分缓解率（55%vs 25%）、无效率（20%vs 75%）、客观有效率（80%vs 25%）、总生存时间[（6.8±1.8）月vs（3.9±1.1）月]、1年生存率（30%vs 5%）等方面比较差异有统计学意义（P〈0.05）,实验组患者治疗效果显著优于对照组。实验组毒副反应较轻,耐受性较好。结论使用多西他赛很好控制了晚期非小细胞肺癌胸腹水的产生,避免了开始就抽胸腹水加速恶液质给患者带来痛苦和缩短生存期,延长了患者生存时间提高了生活质量。
Objective To explore the effect of docetaxel in treatment of pleural fluid and ascites in advanced non-small cell lung cancer（NSCLC）. Methods 40 patients with advanced NSCLC in Ⅳ stage treated in our hospital from January2011 to January 2014 were selected and divided into the study group and the control group, each with 20 patients. Patients in the study group were treated by intravenous injection of single docetaxel per three weeks for at least two courses and then drainage of pleural fluid and ascites or not. Patients in the control group were given supportive treatment with drainage of pleural fluid and ascites. The curative effects and toxic and ide effects in both groups were observed. Results There were significant differences in the overall response rates（25% vs 0%）, partial response rates（55%vs 25%）, no response rates（20% vs 75%）, objective response rates（80% vs 25%）, overall survival [（6.8 ±1.8） m vs（3.9±1.1） m], and 1-year survival rates（30% vs 5%） between two groups（P〈0.05）. The therapeutic effect in the study group was significantly superior than that in the control group with fewer toxic and side effects and better tolerance.Conclusion Docetaxel can control the generation of pleural fluid and ascites in advanced NSCLC, avoid acceleration of dyscrasia and patients＇ pain and shortening of survival caused by early drainage of pleural fluid and ascites, and extend the survival time and improve the living quality of patients.
出处
《中国现代医生》
2016年第5期101-103,共3页
China Modern Doctor
关键词
多西他赛
非小细胞肺癌
肺癌并胸腹水
晚期肺癌
Docetaxel
Non-small cell lung cancer
Lung cancer plus pleural fluid and ascites
Advanced lung cancer
